G A Wiseman - JoVE Visualize

Showing results (11-20 of 23) with videos related to

Pageof 3

Sort By:

Cancer|May 18, 1999

Langerhans cell histiocytosis: diagnosis, natural history, management, and outcomeD M Howarth, G S Gilchrist, B P Mullan, et al.

Cancer|July 1, 1995

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinomaJ A Storlie, J C Buckner, G A Wiseman, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1996

Bone scintigraphy evaluated in diagnosing and staging Langerhans' cell histiocytosis and related disordersD M Howarth, B P Mullan, G A Wiseman, et al.

Chest|September 16, 2000

Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanningM J Krowka, G A Wiseman, O L Burnett, et al.

Blood Cells, Molecules & Diseases|January 1, 1996

Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methodsV F Fairbanks, G G Klee, G A Wiseman, et al.

Thyroid : Official Journal of the American Thyroid Association|August 25, 2000

Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?V Fatourechi, I D Hay, B P Mullan, et al.

Gastroenterology|June 1, 1995

Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibitionC K Tan, P V Podila, J E Taylor, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999

Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibodyG A Wiseman, C A White, T E Witzig, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphomaT E Witzig, C A White, G A Wiseman, et al.

Critical Reviews in Oncology/Hematology|June 22, 2001

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaG A Wiseman, C A White, R B Sparks, et al.

Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:

Pageof 3

Cancer|May 18, 1999

Langerhans cell histiocytosis: diagnosis, natural history, management, and outcomeD M Howarth, G S Gilchrist, B P Mullan, et al.

Cancer|July 1, 1995

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinomaJ A Storlie, J C Buckner, G A Wiseman, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1996

Bone scintigraphy evaluated in diagnosing and staging Langerhans' cell histiocytosis and related disordersD M Howarth, B P Mullan, G A Wiseman, et al.

Chest|September 16, 2000

Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanningM J Krowka, G A Wiseman, O L Burnett, et al.

Blood Cells, Molecules & Diseases|January 1, 1996

Measurement of blood volume and red cell mass: re-examination of 51Cr and 125I methodsV F Fairbanks, G G Klee, G A Wiseman, et al.

Thyroid : Official Journal of the American Thyroid Association|August 25, 2000

Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?V Fatourechi, I D Hay, B P Mullan, et al.

Gastroenterology|June 1, 1995

Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibitionC K Tan, P V Podila, J E Taylor, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999

Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibodyG A Wiseman, C A White, T E Witzig, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphomaT E Witzig, C A White, G A Wiseman, et al.

Critical Reviews in Oncology/Hematology|June 22, 2001

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphomaG A Wiseman, C A White, R B Sparks, et al.

Pageof 3